/IDLDX.ST
IDLDX.ST Stock - IDL Diagnostics AB (publ)
Healthcare|Medical - Diagnostics & ResearchSTO
$0.35-0.29%
$0.00 (-0.29%) • Dec 23
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.38
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IDLDX.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.34 – $0.35
TARGET (TP)$0.40
STOP LOSS$0.32
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.55
52W High$0.60
52W Low$0.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $57.44M | $43.04M | $36.99M | $12.00M | $84,000 |
| Gross Profit | $11.73M | $-2,102,000 | $-2,105,000 | $-5,045,000 | $63,000 |
| Gross Margin | 20.4% | -4.9% | -5.7% | -42.1% | 75.0% |
| Operating Income | $-43,430,000 | $-59,784,000 | $-59,304,000 | $-50,573,000 | $-24,052,000 |
| Net Income | $-42,449,000 | $-59,297,000 | $-58,973,000 | $-50,026,000 | $-19,459,000 |
| Net Margin | -73.9% | -137.8% | -159.4% | -417.0% | -23165.5% |
| EPS | $-0.18 | $-0.26 | $-0.27 | $-0.52 | $-0.26 |
Company Overview
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IDLDX.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | $-0.01 | — | — |
Q3 2025 | Aug 21, 2025 | — | — | — | — |
Q2 2025 | May 7, 2025 | — | $-0.05 | — | — |
Q1 2025 | Feb 19, 2025 | — | $-0.04 | — | — |
Q4 2024 | Oct 24, 2024 | — | $-0.04 | — | — |
Q3 2024 | Aug 21, 2024 | — | $-0.06 | — | — |
Q2 2024 | May 3, 2024 | — | $-0.05 | — | — |
Q1 2024 | Feb 22, 2024 | — | $-0.07 | — | — |
Q4 2023 | Nov 2, 2023 | — | $-0.06 | — | — |
Q3 2023 | Aug 23, 2023 | — | $-0.07 | — | — |
Q2 2023 | May 3, 2023 | — | $-0.06 | — | — |
Q1 2023 | Feb 23, 2023 | — | $-0.07 | — | — |
Q4 2022 | Oct 27, 2022 | — | $-0.05 | — | — |
Q3 2022 | Aug 17, 2022 | — | $-0.07 | — | — |
Q2 2022 | Apr 29, 2022 | — | $-0.09 | — | — |
Q1 2022 | Feb 24, 2022 | — | $-0.24 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.20 | — | — |
Q3 2021 | Aug 31, 2021 | — | $-0.09 | — | — |
Q2 2021 | May 12, 2021 | — | $-0.08 | — | — |
Q1 2021 | Feb 19, 2021 | — | $-0.08 | — | — |
Latest News
Loading news...
Frequently Asked Questions about IDLDX.ST
What is IDLDX.ST's current stock price?
IDL Diagnostics AB (publ) (IDLDX.ST) is currently trading at $0.35 per share. The stock has moved -0.29% today.
What is the analyst price target for IDLDX.ST?
No analyst price targets are currently available for this stock.
What sector is IDL Diagnostics AB (publ) in?
IDL Diagnostics AB (publ) operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the STO exchange.
What is IDLDX.ST's market cap?
IDL Diagnostics AB (publ) has a market capitalization of $0.08 billion, making it a small-cap company.
Does IDLDX.ST pay dividends?
No, IDL Diagnostics AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTI.ST
Active Biotech AB (publ)
$0.04
Mkt Cap: $0.1B
ATORX.ST
Alligator Bioscience AB (publ)
$0.34
Mkt Cap: $0.0B
HEART.ST
Scandinavian Real Heart AB (Publ)
$14.00
Mkt Cap: $0.1B
ICO.ST
Iconovo AB (publ)
$1.14
Mkt Cap: $0.1B
IMMNOV.ST
Immunovia AB (publ)
$0.23
Mkt Cap: $0.1B
LXB.ST
Luxbright AB (publ)
$0.45
Mkt Cap: $0.1B
PILA.ST
Pila Pharma AB (publ)
$2.20
Mkt Cap: $0.1B
SPAGO.ST
Spago Nanomedical AB (publ)
$0.10
Mkt Cap: $0.0B
SPEC.ST
SpectraCure AB (publ)
$0.16
Mkt Cap: $0.1B
SPRINT.ST
Sprint Bioscience AB (publ)
$1.45
Mkt Cap: $0.2B
Explore stocks similar to IDLDX.ST for comparison